Download PDF
Thromb Haemost 1997; 78(06): 1450-1455
DOI: 10.1055/s-0038-1665432
Rapid Communication
Schattauer GmbH Stuttgart

Activation of Coagulation and Fibrinolysis in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome

Corinne H F Nevard
1   The Department of Haematology, Guy’s and St Thomas’ Trust, London, UK
,
Karen M Jurd
1   The Department of Haematology, Guy’s and St Thomas’ Trust, London, UK
,
David A Lane
2   Department of Haematology, Charing Cross and Westminster Medical School, London, UK
,
Helen Philippou
2   Department of Haematology, Charing Cross and Westminster Medical School, London, UK
,
George B Haycock
3   Department of Paediatric Nephrology, Guy’s and St Thomas’ Trust, London, UK
,
Beverley J Hunt
1   The Department of Haematology, Guy’s and St Thomas’ Trust, London, UK
› Author Affiliations
Further Information

Publication History

Received 24 1997

Accepted 04 August 1997

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Diarrhoea-associated haemolytic uraemic syndrome (D+ HUS) is usually caused by verotoxin producing Eschericia coli. We hypothesized that verotoxin binding to glomerular endothelial cells causes localised endothelial cell activation and thus activation of coagulation and reduction of fibrinolytic potential. We also proposed that treatment with fresh frozen plasma or dialysis would not affect these changes. Markers of activation of coagulation and fibrinolysis were measured in 30 children with acute D+ HUS serially, in healthy children and in children on dialysis.

In acute D+ HUS, levels of thrombin-antithrombin III complex and prothrombin fragment 1+2 were significantly increased (p <0.001). The source of thrombin generation was unclear. Factor Xlla levels were increased in patients and controls with renal failure. Factor VIIa levels were not significantly raised in children with acute D+ HUS. D-dimers were increased, but fibrinolytic potential as measured by fibrin plate was reduced. Levels of plasminogen activator inhibitor antigen and activity and tissue plasminogen activator antigen were increased.

Neither peritoneal dialysis nor administration of blood products, the most common treatments, altered parameters of coagulation or fibrinolysis.

 

  • References

  • 1 Frishberg Y, Obrig TG, Kaplan BS. Haemolytic Uraemic Syndrome. In: Paediatric Nephrology. (3rd Ed) Holliday MA, Barratt TM, Avner ED. eds. Williams and Wilkins; Baltimore, Maryland: 1994. pp 871-889
    Google Scholar
  • 2 Milford DV, Taylor CM. New insights into the haemolytic uraemic syndromes. Arch Dis Child 1990; 65: 713-715
    CrossrefPubMedGoogle Scholar
  • 3 Habib R. Pathology of the Haemolytic Uraemic Syndrome. In: Haemolytic Uraemic Syndrome and Thrombocytopenic Purpura. Kaplan BS, Trompeter RS, Moake JL. eds Marcel Decker; New York: 1992. pp 315-353
    Google Scholar
  • 4 Moake JL. Haemolytic-uraemic syndrome: basic science. Lancet 1994; 343: 393-397
    CrossrefPubMedGoogle Scholar
  • 5 Katz J, Lurie A, Kaplan BS, Krawitz S, Metz J. Coagulation findings in the haemolytic uraemic syndrome of infancy: similarity to hyperacute renal allograft rejection. J Pediatr 1971; 78 (03) 426-434
    CrossrefPubMedGoogle Scholar
  • 6 Kisker CT, Rush RA. Absence of intravascular coagulation in the haemolytic uraemic syndrome. Am J Dis Child 1975; 129 (02) 223-226
    PubMedGoogle Scholar
  • 7 Katz J, Krawitz S, Sacks PV, Levin SE, Thompson P, Levin J, Metz J. Platelet, erythrocyte, and fibrinogen kinetics in the haemolytic uraemic syndrome of infancy. J Pediatr 1973; 83 (05) 739-748
    CrossrefPubMedGoogle Scholar
  • 8 Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl JMed 1972; 287 (020) 0999-1005
    CrossrefPubMedGoogle Scholar
  • 9 Taira K, Matsunaga T, Kawahara S, Sakamoto S, Kamitsuji H. Fragments of Urinary Fibrin/Fibrinogen Degradation Products and Cross Linked Fibrin Degradation Products in Various Renal Diseases. Thromb Res 1989; 53: 367-377
    CrossrefPubMedGoogle Scholar
  • 10 Uttley WS. Serum Levels of Fibrin/Fibrinogen Degradation Products in the Haemolytic-Uraemic Syndrome. Arch Dis Child 1970; 45: 587-589
    CrossrefPubMedGoogle Scholar
  • 11 Monnens L, van Aken W, de Jong M. »Active« intravascular coagulation in the epidemic form of haemolytic uraemic syndrome. Clin Nephrol 1982; 17 (06) 284-287
    PubMedGoogle Scholar
  • 12 Monteagudo J, Pereira A, Reverter JC, Pijoan J, Tusell J, Puig L, Ordinas A, Castillo R. Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the haemolytic uraemic syndrome. Thromb Haemost 1991; 66 (05) 515-519
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Petty RG, Pearson JD. Endothelium – the axis of vascular health and disease. J R Coll Physicians Lond 1989; 23 (02) 092-102
    PubMedGoogle Scholar
  • 14 Pober JS, Cotran RS. Cytokines and Endothelial Cell Biology. Physiol Rev 1990; 70 (02) 427-451
    CrossrefPubMedGoogle Scholar
  • 15 Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1896
    CrossrefPubMedGoogle Scholar
  • 16 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66 (01) 67-79
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 van de Kar NCAJ, van Hinsbergh VWM, Brommer EJP, Monnens LAH. The Fibrinolytic System in the Haemolytic Uraemic Syndrome: In Vivo and In Vitro Studies. Pediatr Res 1994; 36 (02) 257-267
    CrossrefPubMedGoogle Scholar
  • 18 Bergstein JM, Riley M, Bang NU. Role of Plasminogen-Activator Inhibitor Type 1 in the Pathogenesis and Outcome of the Haemolytic Uraemic Syndrome. N Engl J Med 1992; 327 (11) 755-759
    CrossrefPubMedGoogle Scholar
  • 19 Chant ID, Milford DV, Rose PE. Plasminogen Activator Inhibitor Activity in Diarrhoea Associated Haemolytic Uraemic Syndrome. QJM 1994; 87: 737-740
    CrossrefPubMedGoogle Scholar
  • 20 Rizzoni G, Claris-Appiani A, Edefonti A, Facchin P, Franchini F, Gusmano R, Imbasciati E, Pavanello L, Perfumo F, Remuzzi G. Plasma infusion for hemolytic uremic syndrome in children: Results of a multicentre controlled trial. J Ped 1988; 112 (02) 284-290
    CrossrefPubMedGoogle Scholar
  • 21 Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J. Treatment of the childhood haemolytic uraemic syndrome with plasma. Pediatr Nephrol 1988; 02: 279-285
    CrossrefPubMedGoogle Scholar
  • 22 Machin SJ, Mackie IJ. Haemostasis. In: Laboratory Haematology. Machin SJ, Mackie IJ. eds Churchill Livingstone; Edinburgh, London, Melbourne, New York: 1989. pp 263-402
    Google Scholar
  • 23 Philippou H, Adami A, Amersey RA, Stubbs PJ, Lane DA. A novel specific immunoassay for plasma two-chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes. Blood 1997; 89: 767-775
    PubMedGoogle Scholar
  • 24 Jurd KM, Stephens CJM, Black MM, Hunt BJ. Endothelial cell activation in cutaneous vasculitis. Clin Exp Dermatol 1996; 21: 28-32
    CrossrefPubMedGoogle Scholar
  • 25 Yamazaki M, Asakura H, Sato T, Tsugawa Y, Matsumura M, Kawamura Y, Ohka T, Matsuda T. Changes in plasma levels of thrombomodulin during haemodialysis. Blood Coagul Fibrinolysis 1992; 02: 113-117
    PubMedGoogle Scholar
  • 26 Stouthard JML, Levi M, Hack CE, Veenhof CHN, Romijn HA, Sauerwein HP, van der PollT. Interleukin-6 stimulates coagulation, not fibrinolysis in humans. Thromb Haemost 1996; 76 (05) 738-742
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 van de KarNC, Sauerwein RW, Demacker PN, Grau GE, van Hinsbergh VW, Monnens LA. Plasma cytokine levels in haemolytic uraemic syndrome. Nephron 1995; 71 (03) 309-313
    CrossrefPubMedGoogle Scholar
  • 28 Dempfle CE, Pfitzner SA, Fahnle M, Heene DL. Measurement of factor XIIa and factor VIIa allows early diagnosis of blood coagulation activation. XVth Congress of the International Society on Thrombosis and Haemostasis Jerusalem. 1995. abstract no 2042
    Google Scholar
  • 29 Borze GJ. The tissue factor pathway of coagulation: factor VII, tissue factor and tissue factor pathway inhibitor. In: Haemostasis and Thrombosis. (3rd Ed) Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds Churchill Livingstone; Edinburgh: 1994. pp 349-377
    Google Scholar